Cargando…

Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?

PURPOSE: Conversion therapy gives some patients with initially unresectable hepatocellular carcinoma (HCC) access to surgery. The purpose of this study was to evaluate the safety and efficacy of hepatectomy after conversion therapy and how it differed from those who undergoing direct hepatectomy. PA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Laihui, He, Yongzhu, Zhu, Guoqing, Xiao, Yongqiang, Song, Shengjiang, Ge, Xian, Wang, Tao, Xie, Jin, Deng, Wei, Hu, Zhigao, Shan, Renfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792109/ https://www.ncbi.nlm.nih.gov/pubmed/36578526 http://dx.doi.org/10.2147/JHC.S388965

Ejemplares similares

Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience
por: Luo, Laihui, et al.
Publicado: (2022)

Pretreatment Neutrophil-to-Lymphocyte Ratio as Prognostic Biomarkers in Patients with Unresectable Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab
por: Xiao, Yongqiang, et al.
Publicado: (2023)

Efficacy of adjuvant TACE on the prognosis of patients with HCC after hepatectomy: a multicenter propensity score matching from China
por: Wu, Zhao, et al.
Publicado: (2023)

Laparoscopic Hepatectomy versus Open Hepatectomy After Conversion Therapy Using Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy for Patients with Initially Unresectable Hepatocellular Carcinoma
por: Yang, Zhenyun, et al.
Publicado: (2023)

Conversion therapy and suitable timing for subsequent salvage surgery for initially unresectable hepatocellular carcinoma: What is new?
por: Zhang, Ze-Feng, et al.
Publicado: (2018)

Case report: Conversion therapy to permit resection of initially unresectable hepatocellular carcinoma
por: Chen, Kang, et al.
Publicado: (2022)

Efficacy of conversion therapy on initially unresectable locally advanced rectal cancer
por: Liu, Tianyu, et al.
Publicado: (2021)

Hepatectomy After Conversion Therapy with Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitors and Anti-PD-1 Antibodies for Initially Unresectable Hepatocellular Carcinoma
por: Yu, Bingran, et al.
Publicado: (2023)

Conversion surgery for initially unresectable extrahepatic biliary tract cancer
por: Oh, Moon Young, et al.
Publicado: (2021)

Splenic Volume, an Easy-To-Use Predictor of HCC Late Recurrence for HCC Patients After Hepatectomy
por: Fang, Tongdi, et al.
Publicado: (2022)

Application of associating liver partition and portal vein ligation for staged hepatectomy for initially unresectable hepatocellular carcinoma
por: Chen, Haoqi, et al.
Publicado: (2022)

Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma
por: Zhu, Xiao-Dong, et al.
Publicado: (2022)

TSC2 Mutations Were Associated with the Early Recurrence of Patients with HCC Underwent Hepatectomy
por: Song, Kangjian, et al.
Publicado: (2021)

Downstaging Conversion Therapy in Patients With Initially Unresectable Advanced Hepatocellular Carcinoma: An Overview
por: Sun, Hui-Chuan, et al.
Publicado: (2021)

Yttrium‐90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study
por: Salem, Riad, et al.
Publicado: (2021)

Protective effect of S-adenosylmethionine on hepatic ischemia-reperfusion injury during hepatectomy in HCC patients with chronic HBV infection
por: Liu, Guo-yan, et al.
Publicado: (2014)

Stereotactic Percutaneous Electrochemotherapy as Primary Approach for Unresectable Large HCC at the Hepatic Hilum
por: Luerken, L., et al.
Publicado: (2021)

Adjuvant ICIs Plus Targeted Therapies Reduce HCC Recurrence after Hepatectomy in Patients with High Risk of Recurrence
por: Yang, Jianming, et al.
Publicado: (2023)

Phase 2 Study of Adjuvant Radiotherapy Following Narrow‐Margin Hepatectomy in Patients With HCC
por: Chen, Bo, et al.
Publicado: (2021)

Surgical indication for and desirable outcomes of conversion surgery in patients with initially unresectable pancreatic ductal adenocarcinoma
por: Satoi, Sohei, et al.
Publicado: (2019)

Impact of conversion surgery after chemotherapy in patients with initially unresectable and recurrent biliary tract cancer
por: Nakamura, Ikuo, et al.
Publicado: (2023)

Combination Therapy of Sorafenib and TACE for Unresectable HCC: A Systematic Review and Meta-Analysis
por: Liu, Lei, et al.
Publicado: (2014)

Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC
por: Li, Ting, et al.
Publicado: (2023)

The role of (18)F−FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy
por: Wang, Guanyun, et al.
Publicado: (2023)

HO-1 is a favorable prognostic factor for HBV-HCC patients who underwent hepatectomy
por: Yeh, Chun-Nan, et al.
Publicado: (2018)

Prognostic value of combined inflammatory and nutritional biomarkers in HCC within the Milan criteria after hepatectomy
por: Feng, Hanxin, et al.
Publicado: (2022)

Corrigendum: The role of 18F−FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy
por: Wang, Guanyun, et al.
Publicado: (2023)

Impact of tumor size and cirrhotic background for differentiating HCC and ICC with CEUS: does it matter for patients undergoing hepatectomy?
por: Jin, Chen, et al.
Publicado: (2017)

The α-RECIST (RECIST 1.1 Combined With Alpha Fetoprotein): A Novel Tool for Identifying Tumor Response of Conversion-Radiotherapy for Unresectable Hepatocellular Carcinoma Before Hepatectomy
por: Xu, Ying, et al.
Publicado: (2022)

Psychometric validation of the EORTC QLQ-HCC18 in patients with previously treated unresectable hepatocellular carcinoma
por: Serrano, Daniel, et al.
Publicado: (2021)

Comparing the long-term efficacy of standard and combined minimally invasive procedures for unresectable HCC: a mixed treatment comparison
por: Zhao, Jianghai, et al.
Publicado: (2016)

Type conversion of secretomes in a 3D TAM2 and HCC cell co-culture system and functional importance of CXCL2 in HCC
por: Lu, Yu, et al.
Publicado: (2016)

Safe standard remnant liver volume after hepatectomy in HCC patients in different stages of hepatic fibrosis
por: Zhang, Zhiming, et al.
Publicado: (2021)

Prediction of early recurrence of HCC after hepatectomy by contrast-enhanced ultrasound-based deep learning radiomics
por: Zhang, Hui, et al.
Publicado: (2022)

Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey Analysis
por: Innominato, Pasquale F., et al.
Publicado: (2022)

Conversion to Resectability Using Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma
por: Li, Binkui, et al.
Publicado: (2021)

Case report and literature review: Conversion surgery for initially unresectable huge retroperitoneal liposarcoma after preoperative radiotherapy
por: Cheng, Sarah Hsin, et al.
Publicado: (2023)

External Radiation versus Internal Radiation for Patients with Advanced Unresectable HCC -A SEER Based Study
por: Wang, Xuan, et al.
Publicado: (2019)

Inflammation-related nomogram for predicting survival of patients with unresectable hepatocellular carcinoma received conversion therapy
por: Wu, Jia-Lin, et al.
Publicado: (2023)

The paradigm of tumor shrinkage and rapid liver remnant hypertrophy for conversion of initially unresectable colorectal liver metastasis: a case report and literature review
por: Xiao, Nan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_a7tghqm6gn1nd61tfmc9danikl